Roger Olsson has been involved in a number of preclinical projects targeting central nervous system and pain/inflammation indications. Dr. Olsson’s responsibilities cover core discovery chemistry including medicinal chemistry, high-throughput medicinal chemistry and analytical chemistry. In addition, he is the program manager of a late phase preclinical discovery project.

Prior to joining ACADIA in 1999 Dr. Olsson worked at Astra, focusing on inflammation. He received a Master of Science in Chemical engineering from the University of Lund Institute of Technology and a PhD in organic chemistry from the University of Lund.